

PRODUCT NAME		
AML-ETO/RUNX1 polyclonal antibody		
Other names: AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2		
<b>Cat. No.</b> pAb-080-050	<b>Type:</b> Polyclonal	<b>Size:</b> 50 µg/ 250 µl
<b>Lot #:</b> A134-0011	<b>Source:</b> Rabbit	<b>Concentration:</b> 0.2 µg/µl

**Description:** Polyclonal antibody raised in rabbit against the AML-ETO (RUNX1) fusion protein, using 3 different KLH-conjugated synthetic peptides. The antibody recognizes the ETO (RUNX1T1) part of the fusion protein.

**Specificity:** Human: positive  
Other species: not tested

Applications	Suggested dilution	References
ELISA	1:100	Fig 1
Western blotting	1:1,000	Fig 2

**Purity:** Affinity purified polyclonal antibody in PBS containing 0.05% azide and 0.05% ProClin 300.


**Storage:** Store at -20°C; for long storage, store at -80°C. Avoid multiple freeze-thaw cycles.

**Precautions:** This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**Last data sheet update:** March 4, 2010


**Target description**

RUNX1T1 (UniProt/Swiss-Prot entry Q06455) is a putative transcription factor which forms a heterodimer with CBFA2T3. Defects in RUNX1T1 have been associated with acute myeloid leukemia (AML-M2) and may be a cause of colorectal cancer.



**Figure 1**  
**Determination of the antibody titer**

To determine the titer of the antibody, an ELISA was performed using a serial dilution of Diagenode antibody directed against AML-ETO (Cat. No. pAb-080-050), crude serum and flow through in antigen coated wells. By plotting the absorbance against the antibody dilution (Figure 1), the titer of the antibody was estimated to be 1:5,250.



**Figure 2**  
**Western blot analysis using the Diagenode antibody directed against AML-ETO**

Figure 2A: Schematic representation of the construction of GST-fusion proteins containing different parts of AML-ETO were constructed and run on a 15% polyacrylamide gel.

Figure 2B: Western blot was performed on seven GST-fusion proteins containing different fragments of AML-ETO (1-7) with the Diagenode antibody against AML-ETO (Cat. No. pAb-080-050), diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. A molecular weight marker (in kDa) is shown on the left; the location of the protein of interest is indicated on the right. The antibody raised against AML-ETO recognizes the ETO part (lane 2) of the fusion protein.

Figure 2C: Western blot was performed on nuclear extracts from KAS-6/1 cells (human myeloma cell line) and SKNO-1 cells (human acute myeloblastic leukaemia) with the Diagenode antibody against AML-ETO (Cat. No. pAb-080-050), diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. On the left, a molecular weight marker is shown (in kDa). The location of AML-ETO and a presumed splice variant (missing 106 C-terminal amino acids) are indicated on the right.